Optimized Diagnosis and Precision Medicine of MODY

Optimized Diagnosis and Precision Medicine of MODY (Maturity-Onset Diabetes of the Young)

The goal of this observation is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed.

The main questions are:

1. The distribution of different types of MODY
2. The phenotypes and clinical characteristics of different types of MODY
3. Response to antidiabetic drugs among different types of MODY

Once the participant is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient/inpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc.

At the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled).

Young-onset type 2 diabetes will be compared to see the difference in clinical presentations and responses to antidiabetic drugs.

Study Overview

• Status: Recruiting
• Conditions: Diabetes Complications; Type 2 Diabetes; Maturity-Onset Diabetes of the Young (MODY)

Detailed Description

Diabetes and its complications rank among the top ten death causes in Taiwan. In Taiwan, besides the high prevalence, diabetes also shows a trend in younger people. Compared with type 2 diabetes which typically develops at older ages, young-onset diabetes (YOD) has a faster decline in the function of islet cells and a higher risk of complications. These young-onset diabetic patients may belong to different subtypes, and each subtype has different clinical manifestations or genetic characteristics, while the physiological and pathological mechanisms behind them are very complex and closely affect the subsequent treatment decisions. Among young-onset diabetes, maturity-onset diabetes of the young (MODY) has the most obvious genetic predisposition and family history. If the diagnosis is confirmed, it may be possible to directly target the unique defect of the relevant gene and accurately select the appropriate drug therapy to help patients achieve good blood sugar control as soon as possible. This five-year proposal is aimed to target 1,500 young-onset diabetic patients (case group) as well as 500 young-onset, but not MODY, diabetic patients (control group). Once the study subject is enrolled, their questionnaire information (including disease course and development, health history, family history, drug history, etc.), medication, outpatient/inpatient medical history, etc. will be collected and logged in. Blood and urine samples will also be collected for biochemical tests genetic testing, etc. At the same time, the investigators will conduct a continuous follow-up on a regular basis (3 months, 6 months, 12 months, 24 months, and 5 years after the study subject is enrolled). The aim of this proposal is to establish a complete registry for the clinical manifestations, environment, genetic, and other related gene variation information of young-onset diabetic patients. Moreover, according to the physiological and pathological mechanisms of different genes, the impact on the clinical characteristics of diabetes, the therapeutic response to drugs, and the impact on complications will be analyzed. It is expected that different subtypes of early-onset diabetes can be established for genetic counseling, prevention, health education, and treatment selection strategies to achieve good blood sugar and other metabolic control in time, so as to achieve individualized precision medical prevention and treatment.

• Study Type: Observational
• Enrollment (Estimated): 1500

Contacts and Locations

• Study Contact: Name: Yi-Jing Sheen, MD. PHD; Phone Number: 4408 886-4-2359-2525; Email: docmedjean@gmail.com

Study Locations

• Taiwan
  • Taichung, Taiwan, 407
    • Recruiting
    • Taichung Veterans General Hospital
    • Contact: Yi-Jing Sheen, MD. PHD; Phone Number: 4408 886-4-2359-2525; Email: docmedjean@gmail.com
    • Sub-Investigator: Wayne H-H Sheu, MD. PHD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Non-Probability Sample

Study Population

Patients with young-onset diabetes who receive regular follow-ups at TCVGH and provide informed consent after fully understanding the study's requirements.

Additionally, direct blood relatives of the case group, including brothers and sisters, who have contacted the research team through the subjects, and have expressed their willingness to participate in this study after granting informed consent

Description

Inclusion Criteria:

1. Case Group Diagnosis of diabetes at or before 25 years of age. BMI (Body Mass Index) of 25 kg/m² or lower. Having at least one parent diagnosed with type 2 diabetes.

2. Family Group Direct blood relatives of the case group, including brothers and sisters of the case group, who have contacted the research team through the subjects.

   Expressing willingness to participate in this study after granting informed consent.

3. Control Group Diagnosis of diabetes occurred at or before the age of 40, and the individual lacks typical MODY (Maturity-Onset Diabetes of the Young) characteristics.

At least one parent has been diagnosed with type 2 diabetes.

Exclusion Criteria:

1. Confirmed Diagnosed with type 1 diabetes.
2. Under 18 years of age.
3. Unable to personally provide informed consent.
4. Patients with unrelieved leukemia.
5. Patients who have undergone chemotherapy or radiation therapy for cancer within the last 12 months.
6. Cases that have received a blood transfusion within the last six months.
7. Unwilling or unable to continue treatment follow-up at this hospital.

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort
Case (MODY); Age at diagnosis of diabetes ≤ 25 years old; and; BMI ≤ 25kg/m2; and; At least one parent suffers from type 2 diabetes
Family; Direct blood relatives/brothers and sisters of the Case group, who have contacted the research team through the subjects and are willing to participate in this study after giving full informed consent.
Control; Age at diagnosis of diabetes ≤ 40 years old, and without typical MODY characteristics; At least one parent suffers from type 2 diabetes

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Glucose control	serum concentration of Fasting glucose (mg/dl) HbA1C (%)	3 months
Genetic testing for evaluate the different types of MODY	Genotype evaluate by WES: Pathogenic or likely pathogenic Vairants rate (%)	1 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Renal function	Concentration of urine albumin-creatinine ratio: UACR (mg/g); Serum creatinine mg/dL	3 months
Sudomotor function	value of Electrochemical Skin Conductance: μS	1 year

Collaborators and Investigators

• Sponsor: Taichung Veterans General Hospital
• Collaborators: National Health Research Institutes, Taiwan
• Investigators: Principal Investigator: Yi-Jing Sheen, MD. PHD, Division of Endocrinology and Metabolism in Taichung Veterans General Hospital

Study record dates

Study Major Dates

• Study Start (Actual): May 22, 2023
• Primary Completion (Estimated): April 21, 2028
• Study Completion (Estimated): May 21, 2028

Study Registration Dates

• First Submitted: October 4, 2023
• First Submitted That Met QC Criteria: October 26, 2023
• First Posted (Actual): November 1, 2023

Study Record Updates

• Last Update Posted (Actual): November 1, 2023
• Last Update Submitted That Met QC Criteria: October 26, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetes Complications
• Other Study ID Numbers: CF23186B

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No